Revolution Medicines Clinical Trials
Revolution Medicines is evaluating potential treatments for RAS mutant cancers through our clinical trials.
Explore how you may be able to participate or get involved.
Explore how you may be able to participate or get involved.
Select Clinical Trials in RAS Mutant Cancer
We have a number of clinical trials evaluating investigational RAS(ON) inhibitors.
RASolute 304
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Status
Active, RECRUITING
Phase
3 (open-label)
Medical Conditions
Pancreatic ductal adenocarcinoma (PDAC)
RASolve 301
Phase 3 Multicenter, Open Label, Randomized Study of Daraxonrasib (RMC‑6236) Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] Non-Small Cell Lung Cancer (NSCLC)
Status
Active, RECRUITING
Phase
3 (open-label)
Medical Conditions
Non-small cell lung cancer (NSCLC)
RASolute 302
Phase 3 Study of Daraxonrasib (RMC‑6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)
Status
Active, NOT RECRUITING
Phase
3 (open-label)
Medical Conditions
Pancreatic ductal adenocarcinoma (PDAC), pancreatic cancer
RMC-LUNG-101
Study of RAS(ON) Inhibitor Combination or Monotherapy in Patients With Advanced RAS-mutated NSCLC
Status
Active, RECRUITING
Phase
1b/2 (open-label)
Medical Conditions
Non-small cell lung cancer (NSCLC); KRAS, NRAS, HRAS mutant NSCLC; KRAS G12C mutant solid tumors, lung cancer; lung cancer stage IV, advanced solid tumor, cancer; RAS G12D mutant NSCLC
RMC-9805-001
Study of Zoldonrasib (RMC-9805) in Participants With KRAS G12D Mutant Solid Tumors
Status
Active, RECRUITING
Phase
1/1b (open-label)
Medical Conditions
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), advanced solid tumors
RMC-GI-102
Study of RAS(ON) inhibitors in Patients With Gastrointestinal Solid Tumors
Status
Active, RECRUITING
Phase
1/2 (open-label)
Medical Conditions
Pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), gastrointestinal cancer
RMC-6291-101
Study of Elironrasib (RMC-6291) in Combination With Daraxonrasib (RMC-6236) in Participants With Advanced KRAS G12C Mutant Solid Tumors
Status
Active, RECRUITING
Phase
1b (open-label)
Medical Conditions
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC)
RMC-6291-001
Dose Escalation and Dose Expansion Study of Elironrasib (RMC-6291) Monotherapy in Subjects With Advanced KRAS G12C Mutant Solid Tumors
Status
Active, NOT RECRUITING
Phase
1/1b (open-label)
Medical Conditions
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), advanced solid tumors
RMC-6236-001
Study of Daraxonrasib (RMC-6236) in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Status
Active, RECRUITING
Phase
1/2 (open-label)
Medical Conditions
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), advanced solid tumors
All RAS(ON) inhibitors discussed here are investigational. Efficacy and safety have not been established.
Discover all our active clinical trials in the complete list available here: ClinicalTrials.gov.
For questions on our clinical trials, please reach out to medinfo@revmed.com or 1-844-2-REVMED (1-844-273-8633).
For questions on our clinical trials, please reach out to medinfo@revmed.com or 1-844-2-REVMED (1-844-273-8633).
